Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NVLN - Novelion Therapeutics Inc.

Previous close
0.68
0.680   100.000%

Share volume: 0
Last Updated: Tue 08 Oct 2019 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 51%
Dept financing 40%
Liquidity 5%
Performance 48%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.68
P/E Ratio 
N/A
DAY RANGE
$0.68 - $0.68
EPS 
-$5.69
52 WEEK RANGE
$0.55 - $2.35
52 WEEK CHANGE
-$45.47
MARKET CAP 
13.341 M
YIELD 
N/A
SHARES OUTSTANDING 
19.619 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$17,312,021
AVERAGE 10 VOLUME 
$56,399
AVERAGE 30 VOLUME 
$165,512
Company detail
CEO: Benjamin J. Harshbarger
Region: US
Website: http://www.novelion.com
Employees: 109
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Novelion Therapeutics, Inc. engages in the development and commercialization of pharmaceuitical products. It focuses in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and is headquartered in Vancouver, Canada.

Recent news